Cartagenia closes US$ 5.9 million (€ 4.25 million) financing round

Boston, MA / Leuven, Belgium: May 2014 - Cartagenia, the leading provider of clinical-grade solutions for genomic assay interpretation and lab reporting to diagnostic genetics labs, clinicians and hospitals, today announced the closing of a $5.9 million (€4.25 million) financing round.

The financing was subscribed by Cartagenia's existing shareholders and management. Shareholders include Capricorn ICT Arkiv, a Leuven-based ICT fund focusing on Digital Healthcare and Big Data, the Flemish investment company PMV and Gemma Frisius Fund, the venture fund of the University of Leuven.

The funds from the financing will be used to expand the company's efforts to commercialize the Cartagenia Bench platform in key markets including North America and Europe. Additionally, the financing will allow Cartagenia to expand its product portfolio in Oncology and Reproductive Health.

For further reading, please go to http://www.capricorn.be/en/news